FIELD: medicine.
SUBSTANCE: group concerns a prolonged delivery of a compstatin analogue, as well as an optional additional active agent when released from a microscopic gel-like inclusion formed if a liquid composition containing the compstatin analogue is introduced into an extravascular space, such as a vitreous chamber of eye in a mammalian body. The invention also refers to a method of treating an individual suffering age-related macular degeneration (ARMD).
EFFECT: improving the compstatin delivery system for the complement system inhibition required for treating ARMD.
58 cl, 4 ex, 6 tbl, 5 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| INJECTION SCHEMES | 2016 |
|
RU2770099C2 |
| DOSING SCHEMES AND CORRESPONDING COMPOSITIONS AND METHODS | 2018 |
|
RU2779495C2 |
| CELL-REACTIVE COMPOSTATIN ANALOGUES, LONG-ACTING COMPSTATIN ANALOGUES OR COMPUTED EFFECT ANALOGUES OF TARGETED ACTION AND RELATED COMPOSITIONS AND METHODS | 2013 |
|
RU2705215C2 |
| CELL-REACTIVE COMPSTATIN ANALOGS, LONG-ACTING COMPSTATIN ANALOGS, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | 2012 |
|
RU2653439C9 |
| POTENT COMPSTATIN ANALOGS | 2012 |
|
RU2656102C2 |
| EFFICIENT COMPSTATIN ANALOGUES | 2006 |
|
RU2474586C2 |
| C3 BINDING AGENTS AND METHODS OF THEIR USE | 2019 |
|
RU2802307C2 |
| IL-6 ANTAGONISTS AND USES THEREOF | 2013 |
|
RU2670943C9 |
| COMPLEMENT FACTOR I AND COMPLEMENT FACTOR I COFACTOR, VECTORS ENCODING THEM AND USE FOR THERAPEUTIC PURPOSES | 2019 |
|
RU2809247C2 |
| PHARMACEUTICAL COMPOSITIONS FOR INHIBITING INFLAMMATORY CYTOKINES | 2019 |
|
RU2816868C2 |
